BIOXYTRAN, INC (BIXT)
Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Bioxytran, Inc.
BIOXYTRAN, INC (BIXT) dilution facts from SEC filings
Snapshot as of Jun 30, 2026, built from 18 SEC filings.
- Shelf registration
- None on file in the filings reviewed
- At-the-market (ATM) program
- No active program in the filings reviewed
- Warrants outstanding
- 6 warrant series recorded as outstanding
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.